Daxor launched its ezBVA Lab send-out diagnostic service at a Kansas health facility, giving outpatient clinicians 24-hour access to quantitative blood volume measurements without capital equipment.
Alpha Score of 49 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Daxor Corporation (Nasdaq: DXR) said Monday it launched a blood volume analysis program at a health care facility in eastern Kansas, extending its outpatient diagnostic footprint deeper into the Midwest.
The program runs on Daxor's ezBVA Lab send-out model, which lets outpatient practices send samples to a CLIA-certified lab and get quantitative blood, plasma, and red cell volume measurements back within 24 hours. The setup requires no capital equipment or dedicated lab space from the provider.
Daxor President and CEO Michael Feldschuh said the model eliminates the logistical barriers that have kept precision volume diagnostics out of outpatient settings, where subjective fluid estimation often leads to readmissions. “Expanding access to outpatient precision diagnostics is critical to breaking the costly cycle of readmissions,” he said in the release.
The company's BVA technology measures total blood volume with 98% accuracy, compared with the clinical estimates that remain standard practice in most heart failure and ICU management. Chief Medical Officer John L. Jefferies said the objective data lets physicians fine-tune decongestion therapy and protect renal function. “Relying on clinical estimates for fluid management routinely leaves subclinical hypervolemia unaddressed or leads to over-diuresis,” he said.
Daxor operates a 20,000-square-foot ISO-certified manufacturing facility in the U.S. and holds FDA clearance for its BVA diagnostic system. The company has been pushing to move its technology beyond hospital-based use into outpatient cardiology centers where the volume of chronic disease management is higher and the financial incentives under value-based care are strongest.
The Kansas launch is the latest in a series of outpatient deployments Daxor has announced this year. The company did not disclose the name of the health care facility or the expected patient volume from the new program.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.